Welcome to our dedicated page for Aspira Women's Health news (Ticker: AWH), a resource for investors and traders seeking the latest updates and insights on Aspira Women's Health stock.
Aspira Women's Health Inc. (Nasdaq: AWH) is a pioneering company focused on the development and commercialization of noninvasive diagnostic tests for gynecologic diseases. The company is at the forefront of women's health, offering innovative solutions that leverage bio-analytical techniques and artificial intelligence.
One of Aspira's flagship products is OvaSuite, a comprehensive portfolio of blood tests designed to assess the risk of ovarian cancer. This suite includes the well-known OvaWatch and Ova1Plus tests. OvaWatch, with a negative predictive value of 99%, is instrumental in evaluating ovarian cancer risk in women with adnexal masses that appear indeterminate or benign, potentially allowing them to avoid unnecessary surgeries. Ova1Plus combines two FDA-cleared tests, Ova1® and Overa®, providing a robust assessment for women scheduled for surgery due to pelvic masses.
In addition to ovarian cancer diagnostics, Aspira is expanding its test pipeline to address other pressing women's health issues. The company is developing EndoCheck, the first-ever noninvasive test for identifying endometriomas, a common form of endometriosis. Another promising test in development is OvaMDx, which combines microRNA and protein biomarkers with patient data to enhance the accuracy of ovarian cancer risk assessments.
The company's commitment to innovation is reflected in its recent achievements. Aspira has published significant clinical studies demonstrating the efficacy of OvaWatch in longitudinal monitoring of ovarian cancer risk, which could significantly reduce surgical backlogs and unnecessary referrals. Furthermore, Aspira has made strides in market access, securing payer coverage from Anthem Blue Cross and expanding its reach to millions of lives across various health plans.
Financially, Aspira has shown remarkable progress. In 2023, the company significantly reduced its operational cash use while increasing revenues and test volumes. These accomplishments were accompanied by important enhancements to their commercial organization and the achievement of key market access milestones. As of December 31, 2023, Aspira had $2.9 million in cash and raised an additional $5.5 million through a registered direct offering and private placement.
The management team, led by CEO Nicole Sandford, has positioned Aspira for substantial growth in 2024 and beyond. The company's forward-looking strategies and robust test pipeline are set to meet the growing demand for noninvasive diagnostics in women's health, offering new hope and improved outcomes for millions of women worldwide.
Aspira Women’s Health Inc. (Nasdaq: AWH) reported a 23.4% increase in OVA1 volume for Q4 2021, reaching 4,750 units, up from 3,849 units in Q4 2020. The number of ordering physicians also rose by 22.8% year-over-year. Aspira is planning staged launches for its new tests, OvaWatch and EndoCheck, with expected developments through 2022. The company’s CEO highlighted the growth in test volumes and the progress in development efforts. Financial results for Q4 and full year 2021 will be discussed in March 2022.
Aspira Women’s Health Inc. (AWH) appointed Minh Merchant as General Counsel and Corporate Secretary, effective January 4, 2022. With extensive experience in healthcare law, Merchant's previous roles include General Counsel at Genome Medical and Associate General Counsel at Myriad Genetics. CEO Valerie Palmieri expressed confidence in Merchant's ability to contribute strategically to the company, known for its innovative women's health solutions. Aspira focuses on improving gynecologic health outcomes, particularly in ovarian cancer risk assessment, and aims to enhance access to specialty tests through its new technology transfer platform.
Aspira Women’s Health Inc. (AWH) reported a strong third quarter with a 34% revenue increase to $1.67 million and a 19% rise in OVA1 test volume to 4,281 units. The company successfully completed Phase 1 of its collaboration with Harvard Dana Farber Cancer Institute. Their OVA1 test now covers over 194 million lives, marking an 8% increase. Despite these gains, expenses surged, with R&D costs up by 155% and marketing expenses up 136%. The company ended the quarter with $44.9 million in cash but reported a cash usage increase to $7.9 million.
Aspira Women’s Health, Inc. (Nasdaq: AWH) will report its third-quarter financial results for the period ending September 30, 2021, on November 10, 2021, before the market opens. Following the release, an investor conference call and webcast will be held at 8:30 a.m. ET. The company focuses on innovative testing options for women’s health, particularly in ovarian cancer risk assessment and pelvic diseases. Its products include OVA1® and OVERA® for ovarian malignancy detection, with ongoing research into new testing solutions like OVANEX™ and EndoCheck™.
Aspira Women’s Health Inc. (Nasdaq: AWH) has partnered with Genoox to enhance women's health through improved testing for complex diseases. This collaboration aims to integrate their genomic data platforms, streamlining access to critical genetic information. It intends to leverage advanced data analytics to accelerate the development of diagnostic solutions, particularly for conditions like ovarian cancer. Both companies foresee expanding their product offerings and enhancing risk assessment tools through this innovative partnership.
Aspira Women’s Health Inc (AWH) and the Black Women’s Health Imperative held a briefing on September 27, 2021, addressing ovarian cancer diagnostics and treatment gaps. Key discussions included the need for education, research funding, improved detection methods, and insurance coverage, especially for underserved populations. Aspira promoted its OVA1plus risk assessment tool, emphasizing its effectiveness among Black women. Ovarian cancer has a mortality rate exceeding 50%, with 60 new cases daily in the U.S. The briefing attracted over 350 attendees, including prominent Congress members, highlighting the urgency to tackle health disparities.
Aspira Women’s Health Inc. (Nasdaq: AWH) has announced partnerships with two leading U.S. women’s health networks and two independent laboratories to enhance access to its OVA1plus™ testing. The agreements, made post the launch of Aspira Synergy, which exceeded commercial milestones, will allow in-house genetic testing for over 950,000 patients annually.
This decentralized platform enables healthcare providers to conduct genetic and ovarian cancer risk assessments directly, leveraging AI technology for improved diagnostics and early detection.
Aspira Women’s Health, Inc. (Nasdaq: AWH) announced its presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference on September 29, 2021, at 4:40 PM ET. The event will include virtual 1x1 meetings with management, and interested parties can request meetings via email. Aspira focuses on innovative testing options for women’s health, particularly in ovarian cancer risk assessment and pelvic diseases. The company is developing next-generation products such as OVAWatch and EndoCheck. For more details, visit www.aspirawh.com.
Aspira Women’s Health (Nasdaq: AWH) is marking Ovarian Cancer Awareness Month by ringing the closing bell at NASDAQ on September 9, 2021, to promote awareness and access to risk assessment for ovarian cancer. Despite being a leading cause of cancer deaths in women, awareness remains low. Aspira aims to enhance knowledge on ovarian cancer through participation in various events, including keynote speeches and congressional briefings. The company is focused on developing innovative testing solutions to improve women’s healthcare and reduce disparities in risk assessment.
Aspira Women’s Health reported a strong second quarter for 2021, with total revenue increasing by 141% to $1.8 million compared to $743,000 in Q2 2020. The volume of OVA1 tests grew by 85% to 4,553 accessions. A recent publication supports OVA1's superiority over standard care for early-stage ovarian cancer detection. However, expenses surged, with research and development costs rising 287% and sales and marketing up by 132%. The company ended the quarter with $53 million in cash but reported a $6.5 million operational cash burn.
FAQ
What is the current stock price of Aspira Women's Health (AWH)?
What is the market cap of Aspira Women's Health (AWH)?
What is Aspira Women's Health Inc. known for?
What products does Aspira offer?
How effective is OvaWatch?
What is Ova1Plus?
What recent achievements has Aspira made?
What is EndoCheck?
How has Aspira performed financially recently?
Who leads Aspira Women's Health Inc.?
What is OvaMDx?
How does Aspira's test pipeline address women's health issues?
